June 2013
Volume 54, Issue 15
ARVO Annual Meeting Abstract  |   June 2013
Relating Improvements in Signs and Symptoms to Duration of Dry Eye Disease (DED) after Treatment with MIM-D3 Ophthalmic Solutions
Author Affiliations & Notes
  • Karen Meerovitch
    Mimetogen Pharmaceuticals, Montreal, QC, Canada
    Department of Pharmacology and Therapeutics, McGill University, Montreal, QC, Canada
  • Teresa Lama
    Mimetogen Pharmaceuticals, Montreal, QC, Canada
  • Debra Schaumberg
    Division of Preventive Medicine, Brigham & Women's Hospital, Harvard Medical School, Boston, MA
    Department of Ophthalmology and Visual Sciences, University of Utah School of Medicine, Salt Lake City, UT
  • Footnotes
    Commercial Relationships Karen Meerovitch, Mimetogen Pharmaceuticals, Inc. (E), Mimetogen Pharmaceuticals, Inc. (P); Teresa Lama, Mimetogen Pharmaceuticals (E), Mimetogen Pharmaceuticals (P); Debra Schaumberg, Pfizer, Inc. (F), Pfizer, Inc. (C), Mimetogen (C), SARcode Bioscience (C), Eleven Biotherapeutics (C)
  • Footnotes
    Support None
Investigative Ophthalmology & Visual Science June 2013, Vol.54, 4340. doi:
  • Views
  • Share
  • Tools
    • Alerts
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Karen Meerovitch, Teresa Lama, Debra Schaumberg; Relating Improvements in Signs and Symptoms to Duration of Dry Eye Disease (DED) after Treatment with MIM-D3 Ophthalmic Solutions. Invest. Ophthalmol. Vis. Sci. 2013;54(15):4340.

      Download citation file:

      © ARVO (1962-2015); The Authors (2016-present)

  • Supplements

Purpose: To explore the clinical outcomes of signs and symptoms after 28 days of treatment with 1% and 5% MIM-D3 ophthalmic solutions as a function of patient reported duration of DED.

Methods: A 2-center, randomized, double-masked, placebo-controlled Phase 2 study was conducted in 150 dry eye patients. Key eligibility criteria included OraCalibra™ scores of ≥ 4, ≥ 2 and ≥ 2 for fluorescein corneal staining (FCS), lissamine green staining, and one symptom from the 4-Symptom Questionnaire, respectively. Additionally, patients had to demonstrate an exacerbation of FCS and ocular discomfort after exposure to a Controlled Adverse Environment (CAESM) on 2 visits, separated by 1-week of BID dosing with artificial tears. Eligible patients were assigned 1:1:1 to study medications (1% MIM-D3, 5% MIM-D3, placebo) and dosed BID for 28 days. Patients recorded morning and evening symptoms in daily diaries. Efficacy measures were FCS post-CAE at Day 28 and patient diary data over the 28-day treatment period. A post-hoc analysis based on duration of DED was performed. Subgroups were created based on the length of time that the patient had reported experiencing dry eye symptoms: 1-5 years, 5-10 years, or >10 years. FCS post-CAE and diary data were evaluated in these subgroups.

Results: Patients who reported having DED for 5-10 years experienced a significant reduction in inferior and total FCS post-CAE, whereas no significant improvements were observed in the patients who reported having DED for 1-5 years or >10 years. The post-CAE staining scores were significantly lower in the 1% MIM-D3 group in inferior (P=0.028) and total cornea (P=0.047) compared to placebo. Patients who reported having DED for 5-10 years also experienced significant improvements for ocular dryness (P=0.029) and grittiness (P=0.035) symptoms in the 1% MIM-D3 group compared to placebo.

Conclusions: These post-hoc data support an association between the duration of DED and the response to MIM-D3 for the reduction in both signs and symptoms. Adjusting for disease duration, patients with reported DED for 5-10 years had a significant treatment effect with 1% MIM-D3 in reducing both FCS and diary symptoms of dryness and grittiness.

Keywords: 466 clinical (human) or epidemiologic studies: treatment/prevention assessment/controlled clinical trials • 486 cornea: tears/tear film/dry eye • 479 cornea: clinical science  

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.